ZWI Therapeutics is a US biotechnology company developing novel protein therapeutics linked to a novel polymer. The company’s new proprietary polymer shows improved pharmacokinetics and reduced potential for immunogenicity compared to existing protein therapeutics polymerized with polyethylene glycol (PEG). These attributes are expected to show enhanced clinical benefits compared to current agents. ZWI has three protein therapeutic programs in preclinical development in rheumatology and rare diseases. ZWI will pursue out-licensing the technology to pharmaceutical companies for use in specific drug development programs. Our platform polymer technology is also broadly useful in the development of nanoparticles and hydrogels.